UroGen Pharma Touts Four-Year Response With Urothelial Cancer Drug Study, Highlights Potential For Bladder Cancer Candidates

UroGen Pharma Ltd. URGN on Sunday highlighted a duration of response of nearly four years from a long-term follow-up study with Jelmyto (mitomycin) for pyelocalyceal solution.The U.S. Food And Drug Administration approved Jelmyto in 2020 for low-grade upper tract urothelial cancer (LG-UTUC) in adults.Among patients from the OLYMPUS trial who achieved a complete response after primary chemoablation with Jelmyto (n = 41), the median duration of response was 47.8 months, regardless of whether their cancer was ...